NCM
CGTX icon

Nantahala Capital Management’s Cognition Therapeutics CGTX Stock Holding History

Nantahala Capital Management’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-192,752
Closed -$407K – 123
2022
Q2 		$407K Sell
192,752
-3,650
-2% -$9.43K 0.02% 106
2022
Q1 		$540K Sell
196,402
-13,186
-6% -$50.8K 0.02% 106
2021
Q4 		$1.32M Buy
+209,588
New +$2.04M 0.05% 115

Other funds holding CGTX

PFO
Pathstone Family Office Englewood, New Jersey $13.1B AUM 21.02% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nantahala Capital Management's CGTX Position: Q3 2022 in Review

Nantahala Capital Management sold out of Cognition Therapeutics (CGTX) in Q3 2022, closing a stake of 192,752 shares — an estimated $407K sold.

Nantahala Capital Management first reported a position in CGTX in Q4 2021 and held it in 3 quarters. The position peaked at $1.32M in Q4 2021. 31 funds tracked by Wall St. Rank hold CGTX as of Q3 2022.

  • Nantahala Capital Management reported no remaining Cognition Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Nantahala Capital Management sold 192,752 Cognition Therapeutics shares in Q3 2022, an estimated $407K.
  • Nantahala Capital Management first reported a position in Cognition Therapeutics in Q4 2021 and held it in 3 quarters.
  • Nantahala Capital Management's Cognition Therapeutics position peaked at $1.32M in Q4 2021.
  • 31 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q3 2022.

Based on Nantahala Capital Management's 13F filing for Q3 2022, filed 10 Nov 2022.